[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fetal-growth-retardation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fetal-growth-retardation":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,47,74,101,130,157,177,206,231,260,284,304],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100336573","investigating-the-structured-use-of-ultrasound-scanning-for-fetal-growth-100336573",false,"NCT03662178","Investigating the Structured Use of Ultrasound Scanning for Fetal Growth","Investigating the Structured Use of Ultrasound Scanning for Fetal Growth (Oxford Growth Restriction Identification Programme (OxGRIP)) on Risk Factors for and the Incidences of Adverse Maternal, Fetal and Neonatal Outcome","OxGRIP","Inclusion Criteria:\n\n• All pregnant women receiving antenatal care at the Oxford University Hospitals NHS Foundation Trust (OUHFT) from January 2013 to 31st December 2019 with no exclusion criteria\n\nExclusion Criteria:\n\n* Women who have opted out of research related to pregnancy in this pregnancy whilst receiving care by the OUHFT.\n* If intrapartum care takes place outside of the OUHFT.",true,"FEMALE","16 Years","60 Years",{"count":22,"type":23},56000,"ESTIMATED","OBSERVATIONAL","Fetal growth restriction during pregnancy represents one of the biggest risk factors for stillbirth (Gardosi et al, 2013), with 'about one in three term, normally formed antepartum stillbirths are related to abnormalities of fetal growth' (MBRRACE, 2015).\n\nTherefore, antenatal detection of growth restricted babies is vital in order to be able to monitor and decide the appropriate delivery timing.\n\nHowever, antenatal detection of SGA babies has been poor, varying greatly across trusts in England in those that calculate their rates (NHS England, 2016). Most trusts do not calculate their detection rates and rates are therefore unknown. It is estimated that routine NHS care detects only 1 in 4 growth restricted babies (Smith, 2015).\n\nOxford University Hospitals NHS Foundation Trust, in partnership with the Oxford Academic Health Science Network (AHSN) has introduced a clinical care pathway (the Oxford Growth Restriction Pathway (OxGRIP)) designed to increase the rates of detection of these at risk babies. The pathway is intended to increase the identification of babies who are at risk of stillbirth, in order to try to prevent this outcome, whilst making best usage of resources, and restricting inequitable practice and unnecessary obstetric intervention.\n\nIt has been developed with reference to a body of research, however, the individual parts of care provided have not been put together in a pathway in this manner before. Therefore it is important to examine whether the pathway meets its goals of improving outcomes for babies in a 'real world' setting.\n\nThe principles of the pathway are\n\n1. A universal routine scan at 36 weeks gestation.\n2. Additional growth scans at 28 and 32 weeks gestation based on a simplified assessment of risk factors and universal uterine artery Doppler at 20 weeks gestation.\n3. Assessment of further parameters other than estimated fetal weight associated with adverse perinatal outcome (eg growth velocity, umbilical artery Doppler and CPR).\n\nThe clinical data routinely collected as a result of the introduction of the pathway offers a valuable and unique resource in identifying and analysing in the effects of the pathway on its intended outcomes and also in investigating and analysing other maternal, fetal and neonatal complications and outcomes, establishing normal \u002F reference ranges for ultrasound values.",[27,28,29,30,31,32,33],"Stillbirth","Fetal Death","Fetal Growth Retardation","Small for Gestational Age","Fetal Growth Restriction","Perinatal Death","Intrauterine Growth Restriction","RECRUITING","2026-01-27",{"date":37,"type":38},"2026-01-29","ACTUAL",{"date":40,"type":38},"2017-09-01",{"date":42,"type":23},"2029-09-30",{"name":44,"class":45},"Oxford University Hospitals NHS Trust","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":17,"sex":18,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":5},"100489302","phase-3-antenatal-melatonin-supplementation-for-neuroprotection-in-fetal-growth-restriction-100489302","NCT05651347","Antenatal Melatonin Supplementation for Neuroprotection in Fetal Growth Restriction","A Triple-blinded, Randomized, Parallel-group Placebo-controlled Trial to Assess the Impact of Maternal Antenatal Melatonin Supplementation on Early Childhood Neurodevelopmental Outcomes in the Setting of Severe Preterm Fetal Growth Restriction","PROTECTMe","Inclusion Criteria:\n\n1. Singleton Pregnancy\n2. Severe fetal growth restriction, defined as:\n\n   * Abdominal circumference ≤3rd centile for gestational age according to charts supplied that have been adapted from Westerway et al; or\n   * Abdominal circumference \\\u003C10th centile in combination with at least one abnormal fetoplacental Doppler study, being:\n\n     * Uterine artery (raised pulsatility index ≥95th centile)\n     * Umbilical artery (pulsatility index ≥95th centile or absent\u002Freversed end-diastolic flow)\n3. Confirmed 23+0 - 31+6 weeks' gestation\n4. Age ≥18 years\n5. Understand English\n\nExclusion Criteria:\n\n1. A fetus with a known chromosomal, major structural anomaly or non-placental cause of fetal growth restriction\n2. Pregnancies requiring immediate delivery (e.g. absent A wave in ductus venosus, preterminal CTG or biophysical profile)\n3. Co-recruitment in another clinical trial where a pharmaceutical product or nutritional supplement impacting on oxidative stress is the trial intervention.\n4. Currently prescribed Fluvoxamine","18 Years",{"count":57,"type":23},336,"INTERVENTIONAL",[60],"PHASE3","Fetal growth restriction (FGR) is a significant health care issue, affecting 20,000 Australian pregnancies every year. Undetected FGR is one of the key risk factors for stillbirth, but FGR can also cause significant impairments in short and long-term health outcomes for the child.\n\nIt is a major risk factor for preterm birth and is a recognised causal pathway to the neurodevelopmental injury underlying cognitive and behavioural impairment and cerebral palsy. Current obstetric care is focused on the detection of the growth restricted fetus and then ultrasound assessment of fetal wellbeing to guide timing of delivery. This approach seeks to maximize the gestational age of the fetus at delivery to minimise the risks of prematurity, while delivering the fetus in time to reduce the likelihood of stillbirth. Currently, no therapies exist that can maximize fetal wellbeing in the setting of growth restriction and minimise the frequency of antenatally acquired brain injury due to in-utero hypoxia.\n\nThis triple-blind, randomized, parallel group, placebo-controlled trial will administer maternal melatonin or placebo supplementation antenatally in the setting of early-onset severe FGR to determine whether melatonin can PROTECT the fetal brain and lead to improved neurodevelopmental outcomes.",[29,63,64],"Stillbirth and Fetal Death","Pregnancy Preterm","2025-06-03",{"date":67,"type":38},"2025-06-06",{"date":69,"type":38},"2019-05-29",{"date":71,"type":23},"2027-04-30",{"name":73,"class":45},"Monash University",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":58,"phases":84,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":46},"100589312","validation-of-sensors-for-long-term-non-invasive-fetal-monitoring-100589312","NCT06952777","Validation of Sensors for Long-term Non-Invasive Fetal Monitoring","Measurement and Validation of Fetal Heart and Fetal Movement Signals Detected Via Non-adhesive Sensors","Inclusion Criteria:\n\n* Participants will be included if they have a non-anomalous singleton pregnancy after 28 weeks' gestation with an estimated fetal weight \\>10th centile \\\u003C 90th centile. Participants will be 16 years or over in order that they can give independent consent.\n\nExclusion Criteria:\n\n* Participants will be excluded if there are fetal anomalies (as defined by the NHS Fetal Anomaly Screening Programme - https:\u002F\u002Fwww.gov.uk\u002Fguidance\u002Ffetal-anomaly-screening-programme-overview), it is a multiple pregnancy, there is evidence of Fetal Growth Restriction (Estimated Fetal Weight \\\u003C10th centile) or if participants cannot speak or do not understand fluent English. Participants will not be able to participate if they are unable to give informed consent. Participants \\\u003C16 years of age will be excluded from this study.","50 Years",{"count":83,"type":23},69,[85],"NA","A multidisciplinary team of a doctor and engineers have developed a new sensor that will be able to detect mothers' and babies' heartbeat and babies movements in late pregnancy. This sensor can be placed in contact with the mothers' skin over the pregnant uterus without having to be stuck down. We anticipate that this sensor would allow us to monitor babies for longer periods of time which might help us to better identify babies who are being deprived of oxygen during pregnancy. We need to test these sensors on women in late pregnancy for two reasons. Firstly, we need to ensure they reliably measure mother and babies heart rates without interference from movement or other electrical equipment. Secondly we need to ensure that the information they provide is accurate (compared to current measurement techniques).\n\nWe will carry out two related studies. The first will include up to 24 women to develop the sensors to ensure that they can obtain consistent signals from mothers' and babies' heartbeats without interference from movement and other electronic devices. We will adjust the electronics in the sensors to ensure they give the best signal. The second will include up to 45 women to see whether the information detected by the sensors is comparable to existing technologies. This information will help us to see whether these sensors can be organised into a new device for fetal monitoring which can then be tested.",[88,29],"Fetal Distress With Antenatal Problem",[90,91],"Fetal monitoring","Fetal heart rate monitoring","2025-04-23",{"date":94,"type":38},"2025-05-01",{"date":96,"type":38},"2024-06-01",{"date":98,"type":23},"2025-12-31",{"name":100,"class":45},"University of Manchester",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":18,"minAge":55,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":58,"phases":112,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":4},"100516876","stv-analysis-versus-visual-evaluation-of-cardiotocography-in-fgr-100516876","NCT06010238","STV Analysis Versus Visual Evaluation of Cardiotocography in FGR","Short Term Variation Analysis Versus Visual Evaluation of Cardiotocography in Fetal Growth Restriction","SAVEFGR","Inclusion Criteria:\n\n* Pregnant women with a singleton pregnancy between 24 weeks and 0 days and 31 weeks and 6 days with severe, early-onset fetal growth restriction, admitted in hospital or frequently evaluated ambulatory by CTG (according to local protocol) for fetal monitoring.\n* Fetal growth restriction is defined in line with the international Delphi consensus as biometric ultrasound measurement of the abdominal circumference (AC) OR a combination of measurements resulting in an estimated fetal weight (EFW) below the 3rd percentile (\\\u003Cp3) OR a combination of EFW \\\u003Cp10 AND uterine artery pulsatility index (PI) \\>p95 OR umbilical artery Doppler PI \\>p95.\n* Maternal age ≥ 18 years.\n* Able to provide written informed consent for collection and use of data on informed consent form in available language.\n\nExclusion Criteria:\n\n* Known congenital or chromosomal anomalies influencing perinatal outcome.\n* Imminent labour or expected maternal indication for delivery \\\u003C 48 hours.","99 Years",{"count":111,"type":23},800,[85],"This stepped wedge cluster randomized clinical trial investigates whether in pregnant women with severe, early-onset fetal growth restriction, the use of STV analysis in fetal monitoring improves the chances of perinatal survival, compared with visual evaluation of the cardiotocography.",[29],[116,117,118,119],"fetal growth restriction","cardiotocography","perinatal death","short term variation","NOT_YET_RECRUITING","2024-08-07",{"date":123,"type":38},"2024-08-09",{"date":125,"type":23},"2025-01-01",{"date":127,"type":23},"2029-01-01",{"name":129,"class":45},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":17,"sex":138,"minAge":4,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":156},"100417821","bioimpedence-and-arterial-function-monitoring-at-birth-and-in-infants-100417821","NCT04720690","Bioimpedence and Arterial Function Monitoring at Birth and in Infants","Bioimpedence and Arterial Function Monitoring at Birth and in Infants: the BAMBI Study","BAMBI","Inclusion Criteria:\n\n* Healthy term infants (including those with SGA+\u002F-FGR) in the postnatal ward\n* Term and Preterm infants (including those with SGA+\u002F-FGR) admitted to the neonatal unit\n* Written informed parental consent\n\nExclusion Criteria:\n\n* Antenatal or postnatal diagnosis of complex\u002Flife-limiting congenital anomaly or genetic condition\n* Infants with no realistic chance of survival\n* Infants with fragile skin not permitting use of cuffs for research purposes\n* Babies whose parents have a limited understanding of English will be excluded in the event that communication via NHS translation services is not possible due to clinical demands on these services","ALL","6 Months",{"count":141,"type":23},120,"Babies may be born appropriately grown for gestational age (AGA, \\>10th centile) or small for gestational age (SGA, \\\u003C10th centile). Babies who are SGA and have evidence in utero of vascular compromise using antenatal doppler indices are classified as having fetal growth restriction (FGR). Babies with FGR are at increased risk of cardiovascular disease in adult life. Increased arterial stiffness and intima-media thickness are thought to mediate this risk in adults. It is not known how early in life these changes can be robustly detected. In addition, very little is known generally about how babies' hearts and arteries change in structure and function over the first year of life, whether affected by SGA or not. This study aims to understand if there are differences in cardiac and arterial structure and function between babies born AGA or SGA. Within the group of SGA babies, the study team will investigate whether FGR and maternal pre-eclampsia influence these measurements. The effects gestational age on these parameters will be studied within all groups: half of the babies recruited will be \\\u003C32 weeks gestational age (GA), and half will be ≥32 weeks GA. Study participants will have further measurements at 3-6 months of life to assess if cardiac and arterial structure and function change in babies over the first year of life. The study team will use the Vicorder device to measure arterial stiffness, and assess the feasibility of using this device in neonates. The Vicorder will also be used to measure cardiac output. The feasibility and validity of this device for this purpose will be investigated (Vicorder is not validated for cardiac output measurement in infants). Vicorder cardiac output results will be compared to echocardiography and bioimpedence technology (using the NICaS monitor). The study team will use ultrasound for arterial structure measurements of the carotid artery and aorta.",[144,29,145,146],"Arterial Stiffness","Small for Gestational Age at Delivery","Pre-Eclampsia","2024-07-26",{"date":149,"type":38},"2024-07-29",{"date":151,"type":38},"2020-12-01",{"date":153,"type":23},"2024-12-31",{"name":155,"class":45},"Imperial College Healthcare NHS Trust",2,{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":18,"minAge":55,"maxAge":163,"enrollmentInfo":164,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":46},"100523524","prediction-of-placental-fetal-growth-restriction-in-high-risk-population-popfgr-100523524","NCT06096805","Prediction of Placental Fetal Growth Restriction in High Risk Population (PoPFGR)","Inclusion Criteria:\n\n* Pregnant women with gestational age of \\\u003C14 weeks\n* Maternal age between 18 and 45 years old\n* With at least one of FGR high risk factors:\n\n  1. Maternal age \\>40 years\n  2. Nulliparous, Maternal age \\>38 years\n  3. Previous pregnancy with FGR, PE or placental abruption\n  4. Maternal medical history of chronic hypertension, diabetes mellitus, chronic nephritis or autoimmune diseases (such as SLE or APS)\n  5. Recurrent spontaneous abortion (RSA) \\> 3 times with unknown causes\n* Or with at least two of the following FGR high risk factors:\n\n  1. Maternal age 35\\~40 years\n  2. BMI ≥ 28 kg\u002Fm2 or BMI \\\u003C 18.5 kg\u002Fm2\n  3. Conception with assisted reproductive technology\n  4. Interval from previous delivery: \\> 5 years or \\\u003C 6 months\n\n     Exclusion Criteria:\n* Presence of fetal genetic abnormalities or severe structural abnormalities in prenatal ultrasound or genetic testing.","45 Years",{"count":165,"type":23},2000,"This study intends to prospectively enroll high-risk pregnant women to establish a multicenter cohort. By combining maternal basic characteristics, medical history, early pregnancy ultrasound, and biological markers, we aim to construct a joint predictive model for MVM-FGR.",[29],"2024-06-06",{"date":170,"type":38},"2024-06-07",{"date":172,"type":38},"2023-08-10",{"date":174,"type":23},"2025-12-30",{"name":176,"class":45},"Shanghai First Maternity and Infant Hospital",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":18,"minAge":55,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":58,"phases":187,"briefSummary":188,"conditions":189,"keywords":192,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":201,"leadSponsor":203,"locationsCount":205},"100461118","management-of-early-onset-fetal-growth-restriction-angiogenic-factors-versus-feto-placental-doppler-100461118","NCT05284474","Management of Early-onset Fetal Growth Restriction: Angiogenic Factors Versus Feto-placental Doppler","Management of Early-onset Fetal Growth Restriction: Angiogenic Factors Versus Feto-placental Doppler (Early GRAFD)","earlyGRAFD","Inclusion Criteria:\n\n* Pregnant women of at least 18 years old\n* Singleton pregnancy\n* Ultrasonographic EFW ≤10th percentile between 26+0 and 31+6 weeks of gestation\n* Gestational age confirmed by fetal crown-rump length measurement during the first trimester scan (from 11+0 to 13+6 weeks of gestation) or by in vitro fertilization dates.\n\nExclusion Criteria:\n\n* Major fetal malformations or genetic disorders\n* Fetal death\n* Refusal to give informed consent\n* Stage IV FGR",{"count":186,"type":23},340,[85],"This is a multicentre, open-label, randomized controlled trial. A total of 340 singleton pregnancies with an EFW ≤10th percentile between 26+0 and 31+6 weeks will be recruited and randomly allocated to either the control or the intervention group. In the control group, standard Doppler-based management will be used. In the intervention group, different soluble fms-like tyrosine kinase to placental growth factor ratio (sFlt-1\u002FPlGF) cutoffs will be incorporated to the current protocol to adjust the frequency of ultrasounds and to plan elective delivery.",[29,190,191],"Preeclampsia","Placenta Diseases",[116,193,194,195,196],"small for gestational age","PlGF","sFlt-1","Doppler","2024-06-03",{"date":199,"type":38},"2024-06-04",{"date":197,"type":23},{"date":202,"type":23},"2026-12-30",{"name":204,"class":45},"Hospital Universitari Vall d'Hebron Research Institute",27,{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":18,"minAge":55,"maxAge":163,"enrollmentInfo":214,"targetDuration":216,"studyType":24,"phases":4,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":4},"100542187","pregnancy-repository-100542187","NCT06339606","Pregnancy Repository","Repository for Biospecimens From Pregnant Patients","PR","Inclusion Criteria:\n\n* Consenting pregnant adults (age 18-45 years) with known or suspected risk for abnormal placentation (Abnormal Placentation Group)\n* Consenting pregnant adults (age 18-45 years) with low-risk pregnancies (Control Group)\n* Singleton or multiple pregnancy\n* Ongoing clinical care at the participating sites, with delivery at the same institution.\n\nExclusion Criteria:\n\n* None",{"count":215,"type":23},7000,"9 Months","An essential part of clinical research is the availability and accessibility of human biospecimens for the identification of biomarkers, new treatments and measurement of response to therapy. Proteins, RNA and DNA can be extracted and studied as well. This is a critical first step in performing many fundamental molecular biology experiments. A variety of biospecimens are utilized for research including but not limited to normal and malignant tissues, blood, and other body fluids.\n\nIn order to obtain high-quality biospecimens, they must be acquired serially, stored according to current standards, and matched with clinical information for maximum value. As such, the investigators would like to create a repository of biospecimens collected from pregnant patients who are seen at Mount Sinai Hospital and other research hospitals in Toronto. Mount Sinai provides personnel and infrastructure to serve the largest (7500 births\u002Fyear) and highest complex Maternity program in Ontario. Of the 7500 patients a year, at least 2500 are considered high risk pregnancies, where there's a possibility of preeclampsia, placenta accreta and a host of other complications. For this study, biological specimens - blood, cervical and placental samples - will be collected from these high-risk groups in order to better understand the causes of the underlying conditions.",[219,29,220,190,221],"Pregnancy Related","Placental Insufficiency","Cervix; Pregnancy","2024-04-22",{"date":224,"type":38},"2024-04-24",{"date":226,"type":23},"2024-05-01",{"date":228,"type":23},"2031-04-30",{"name":230,"class":45},"Sunnybrook Health Sciences Centre",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":138,"minAge":55,"maxAge":81,"enrollmentInfo":238,"targetDuration":240,"studyType":24,"phases":4,"briefSummary":241,"conditions":242,"keywords":246,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":259},"100512448","selective-fetal-growth-restriction-in-monochorionic-twins---an-international-investigation-100512448","NCT05952583","Selective Fetal Growth Restriction in Monochorionic Twins - an International Investigation","CONTRAST","Inclusion Criteria:\n\n* MCDA twin pregnancy\n* Diagnosis of sFGR before 28+0 weeks of GA (independent of Doppler flows)\n* Pregnant woman ≥ 18 years and able to consent\n* Partner (who has (future) parental responsibility - if applicable) ≥ 18 years and able to consent\n* Written informed consent of both parents (if applicable) for participation in the longitudinal follow-up until 2 years after birth)\n\nExclusion Criteria:\n\n* The presence of lethal anomalies (one or both fetuses)\n* Multiple pregnancy higher order than twins;\n* TTTS\u002FTAPS present at moment of sFGR diagnosis.",{"count":239,"type":23},274,"2 Years","Optimal diagnostic management and underlying pathophysiological mechanisms of selective fetal growth restriction (sFGR) in monochorionic diamniotic (MCDA) twin pregnancies have not been fully clarified.\n\nThe current diagnostic classification system based on three different umbilical artery flow patterns has no increasing scale of severity and the predictive value is limited. Since there is no treatment available for sFGR, predicting fetal deterioration is key in preventing single or double fetal demise. Outcome prediction is furthermore important in the selection of cases that will be offered selective reduction (to provide the larger twin with better prospects), as well as determining monitor frequency and possible hospital admission. As outcome prediction is clinically challenging, patient counselling is too, and parents often encounter a great deal of uncertainty during the pregnancy.\n\nFurthermore, little is known about the brain development of sFGR children (both during pregnancy and after birth). Moreover, the psychological impact of an sFGR pregnancy of the future parent)s) has not been studied before. The impact of these factors should be taken into account during patient counseling, which is currently not the case.\n\nBy our knowledge, this is the first international, multicenter, prospective cohort study on that will address the abovementioned questions and knowledge gaps in MCDA pregnancies complicated by selective fetal growth restriction.",[243,29,244,245],"Twin; Pregnancy, Affecting Fetus or Newborn","Twin Monochorionic Diamniotic Placenta","Twin Diseases",[247,248,249],"sFGR","sIUGR","selective fetal growth restriction","2024-04-12",{"date":252,"type":38},"2024-04-15",{"date":254,"type":38},"2023-02-17",{"date":256,"type":23},"2028-03-01",{"name":258,"class":45},"Leiden University Medical Center",6,{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":18,"minAge":55,"maxAge":4,"enrollmentInfo":266,"targetDuration":4,"studyType":58,"phases":268,"briefSummary":269,"conditions":270,"keywords":271,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":259},"100442213","fetal-brain-care-therapies-for-brain-neurodevelopment-in-fetal-growth-restriction-100442213","NCT05038462","Fetal Brain Care: Therapies for Brain Neurodevelopment in Fetal Growth Restriction","Inclusion Criteria:\n\n* Singleton pregnancies\n* Non-malformed fetus\n* Pregnancies with fetal growth restriction\n* 24-32.6 weeks of gestation\n\nExclusion Criteria:\n\n* Chromosomal or structural abnormalities diagnosed during pregnancy or in the neonatal period\n* Critical Doppler study suggesting the need for delivery within the next 14 days at the time of diagnosis: reverse end-diastolic velocity in the umbilical artery or ductus venosus pulsatility \\>95th centile\n* Maternal mental or psychiatric disorders\n* Maternal allergy to cow's milk protein",{"count":267,"type":23},304,[85],"Singleton pregnancies being diagnosed of fetal growth restriction from 24 to 32.6 weeks of gestation will be randomized to two equally sized groups: maternal oral supplementation with Lactoferrin and DHA (Docosahexaenoic acid) or placebo.",[29,33],[29,31,33,272,273,274],"Neurodevelopment","Lactoferrin","DHA","2024-03-15",{"date":277,"type":38},"2024-03-18",{"date":279,"type":38},"2023-01-18",{"date":281,"type":23},"2026-12",{"name":283,"class":45},"Institut d'Investigacions Biomèdiques August Pi i Sunyer",{"id":285,"slug":286,"hasResults":11,"nctId":287,"briefTitle":288,"officialTitle":288,"acronym":289,"eligibilityCriteria":290,"healthyVolunteers":17,"sex":18,"minAge":55,"maxAge":163,"enrollmentInfo":291,"targetDuration":216,"studyType":24,"phases":4,"briefSummary":293,"conditions":294,"keywords":4,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":300,"leadSponsor":302,"locationsCount":4},"100540925","optimization-of-cervical-collections-in-pregnancy-100540925","NCT06323187","Optimization of Cervical Collections in Pregnancy","OCCP","Inclusion Criteria:\n\n* Confirmed pregnancy Before 30w0d gestation for pregnant participants\n* Regular menses within previous month for non-pregnant participants\n* 18-45 years old\n\nExclusion Criteria:\n\n* Bleeding \\>5 days in first trimester for pregnant participants\n* Ruptured membranes for pregnant participants\n* Currently menstruating for non-pregnant participants",{"count":292,"type":23},2600,"Fetal cells are not easily obtained from pregnant patients; this curtails testing to assess the health of the fetus and the mother. Currently, the only way of diagnosing fetal genetic or chromosomal abnormalities is by invasive techniques, such as chorionic villous sampling (CVS) and amniocentesis performed at 10 to 13 weeks and after 15 weeks of gestation, respectively. Although small, there is a risk for fetal loss with these procedures. Transcervical cell sampling (TCS), similar to a Pap smear, is a platform that meets the requirements for prenatal genetic testing (genetic testing with fetal cells obtained before birth), as well as diagnosis of maternal pregnancy complication, at a very early stage of pregnancy (as early as 5 weeks) and carries low risk for the mother and the developing fetus.\n\nThis study will examine cervical fluid collected using various noninvasive methods for TCS in pregnant women. The number of placental cells will be assessed against similarly obtained samples from nonpregnant women of reproductive age who lack cells derived from a placenta. Participating volunteers will provide written informed consent. Only standard medical procedures and approved devices will be used for collection of cervical fluid, minimizing risk to the participants and their fetuses. No test results or other benefits will be available to the participants.",[221,295,190,29],"Inherited Genetic Conditions (Diagnosis)","2024-03-14",{"date":298,"type":38},"2024-03-21",{"date":226,"type":23},{"date":301,"type":23},"2031-02-28",{"name":303,"class":45},"Dr. Sascha Drewlo",{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":17,"sex":18,"minAge":55,"maxAge":310,"enrollmentInfo":311,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":312,"conditions":313,"keywords":316,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":4},"100453709","study-of-pregnancy-pathologies-associated-with-placental-abnormalities-100453709","NCT05188066","Study of Pregnancy Pathologies Associated With Placental Abnormalities","Inclusion Criteria:\n\nAdult women\n\n* Admitted to the CHUGA for a birth or an abortion.\n* Pregnant women consenting to the collection of their fetal placenta membranes, during premature deliveries or at term of pregnancy OR Women performing an abortion consenting to the collection of their abortion products.\n* Having signed a consent\n* Affiliated with social security\n\nExclusion Criteria:\n\n* Placental sample or abortion product unavailable (not collected or necessary for treatment).\n* Patient with known positive HIV or Hepatitis B or Hepatitis C serology or at risk according to the infectious safety criteria applied by the EFS.\n* hemoglobin \\\u003C7d \u002F dL or hemoglobin \\\u003C10g \u002F dL if she suffers from a cardio-respiratory pathology).\n* Patient protected by law (minor, hospitalized under duress, subject to a legal protection measure by guardianship or curatorship, deprived of liberty by judicial or administrative decision)","52 Years",{"count":111,"type":23},"Pregnancy pathologies can occur from implantation until childbirth. The investigators are interested in the development mechanisms of these pathologies and aim to develop therapies to treat them.\n\nThe investigators need to collect samples, especially placental samples, following abortions and term and premature deliveries. Abortions will allow investigators to have non-pathological placental material up to 13 weeks. This material will serve as a reference for the understanding of the histological changes that occur in normal placentas collected at term of pregnancy. The latter will, in turn, be compared with the placentas collected during premature deliveries. Also, the abortion product will be cultivated in an environment mimicking the pathology of pre-eclampsia. This study will allow investigators to advance their understanding of the pathophysiological mechanisms of the placenta. The investigators are internationally recognized for their research on these pathologies.",[314,315,29],"Pre-eclampsia","Pre-Term",[317,318,319,320,321],"pre-eclampsia","fetal growth retardation","placenta histology","vascularization","trophoblast proliferation","2022-01-07",{"date":324,"type":38},"2022-01-12",{"date":326,"type":23},"2022-01-06",{"date":328,"type":23},"2030-01-31",{"name":330,"class":45},"University Hospital, Grenoble"]